<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04265599</url>
  </required_header>
  <id_info>
    <org_study_id>VEK RegionH: H-19010297</org_study_id>
    <nct_id>NCT04265599</nct_id>
  </id_info>
  <brief_title>Exploring Pathogenesis and Treatment of Hypercalcemia Caused by Intramuscular Injection of Paraffinoil</brief_title>
  <official_title>Hypercalcemia After Cosmetic Paraffin Oil Injections: Unravelling Etiology, Pathogenesis and Potential Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to characterize paraffin oil induced granulomatous disease. We will
      investigate pathogenesis and natural history of paraffin disease. Subsequently, through
      further translational studies, we intend to identify novel treatments to be tested in future
      randomized clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with concentration of ionized calcium in plasma above normal range = Hypercalcemia</measure>
    <time_frame>at first examination or developed during observation period until 2025</time_frame>
    <description>Hypercalcemia in plasma (exploratory not intervention study). yes or no and level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with concentration of parathyroid hormone PTH in plasma below normal range</measure>
    <time_frame>at first examination or developed during observation period until 2025</time_frame>
    <description>PTH level in plasma indicator of hypercalcemia</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypercalcemia</condition>
  <condition>Renal Injury</condition>
  <condition>Paraffinoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples Muscle tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        General population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  previous intramuscular injection of paraffin or other oil

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ebbe Eldrup, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ebbe Eldrup, DMSc</last_name>
    <phone>+45 38681154</phone>
    <email>ebbe.eldrup@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Theilade, DMSc</last_name>
    <email>karen.simone.theilade@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ebbe Eldrup, DMSc</last_name>
      <phone>+45 38681154</phone>
      <email>ebbe.eldrup@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Simone Theilade, DMSc</last_name>
      <email>karen.simone.theilade@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Ebbe Eldrup, MD, DMSc</investigator_full_name>
    <investigator_title>Principal investigator Consultant Endocrinologist MD DMSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercalcemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

